Search
Illinois Paid Clinical Trials
A listing of 2669 clinical trials in Illinois actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1957 - 1968 of 2669
Illinois is currently home to 2669 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Chicago, Peoria, Springfield and Urbana. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Featured Trial
Healthy Participants Needed (Colonoscopy + Cancer Screening)
Recruiting
Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
Conditions:
Healthy
Healthy Volunteers
Healthy Subjects
Healthy Volunteer
Healthy Participants
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Conditions:
Healthy
Healthy Volunteer Study
Featured Offer
Lose 20% of Body Weight With GLP-1's
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to tirzepatide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
Semaglutide and Tirzepatide are advanced GLP-1 medications designed to support weight management and metabolic health. They work by targeting GLP-1 receptors in the body, helping regulate appetite, improve blood sugar control, and support sustainable weight loss (up to 22% of body weight).
Get $50 off your first order using promo code: policy-lab-50
Semaglutide and Tirzepatide are advanced GLP-1 medications designed to support weight management and metabolic health. They work by targeting GLP-1 receptors in the body, helping regulate appetite, improve blood sugar control, and support sustainable weight loss (up to 22% of body weight).
Get $50 off your first order using promo code: policy-lab-50
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Chronic Cough Study
Recruiting
Are you tired of living with chronic cough? The ASPIRE Study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough. You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you.
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Allergic Asthma
Featured Trial
Buy Retatrutide Online Through Celia
Recruiting
Retatrutide (formerly M25) is an investigational peptide being studied for its potential in supporting weight management and metabolic health. It acts on GLP-1, GIP, and glucagon receptors to influence appetite, energy regulation, and fat metabolism.
Conditions:
Healthy
A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)
Recruiting
This is a Phase 2 superiority study of LBP-EC01, a recombinant bacteriophage cocktail, with an initial open-label 3-arm pharmacokinetic (PK) lead-in portion of 30 patients to evaluate the optimal dosing regimen to be used in the subsequent 288 patient blinded portion of the study which will be randomized 1:1 comparing LBP-EC01 + antibiotic versus placebo + antibiotic in patients with a history of prior urinary tract infection (UTI) cased by E. coli. All patients will be required to have an activ... Read More
Gender:
FEMALE
Ages:
Between 18 years and 75 years
Trial Updated:
02/24/2025
Locations: Research Site 117, Northbrook, Illinois
Conditions: Urinary Tract Infections
Study of the Research Medicine CIN-103 in Adults with Irritable Bowel Syndrome with Predominant Diarrhea (IBS-D).
Recruiting
The goal of this clinical trial is to evaluate if the study drug, CIN-103, can help reduce the symptoms associated with irritable bowel syndrome with predominant diarrhea (IBS-D) in adult patients. The main questions it aims to answer are:
* To evaluate the efficacy of CIN-103 on symptoms of IBS-D when given to patients with IBS-D compared to a placebo.
* To evaluate the safety and tolerability of CIN-103 when given to patients with IBS-D compared to a placebo
Participants will attend the foll... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: Southwest Gastroenterology, Oak Lawn, Illinois
Conditions: Irritable Bowel Syndrome With Diarrhea
Time Restricted Eating with or Without a Fiber Supplement for Weight Management in Pediatric Cancer Survivors
Recruiting
This study aims to address a critical gap in pediatric oncology survivorship care by exploring innovative solutions to addressing obesity and its comorbidities in pediatric cancer survivors. The majority (99%) of pediatric cancer survivors will develop severe chronic health conditions by age 50, with 96% developing at least one severe/disabling, life threating or fatal chronic health condition. Obesity, cardiovascular, and metabolic diseases are the most common treatment-related late effects amo... Read More
Gender:
ALL
Ages:
Between 18 years and 39 years
Trial Updated:
02/21/2025
Locations: University of Illinois at Chicago, Chicago, Illinois
Conditions: Weight, Body
A Study Evaluating AB248 Alone or in Combination with Pembrolizumab in Adult Patients with Solid Tumors
Recruiting
This is a phase I, First-in-Human (FIH), open-label study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of AB248 as monotherapy OR in combination with pembrolizumab in adult participants with locally advanced or metastatic solid tumors. The study will consist of a dose escalation and a dose expansion stage.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: University of Chicago Medical Center, Chicago, Illinois
Conditions: Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Squamous Cell Carcinoma of Head and Neck, Renal Cell Carcinoma
Time Restricted Eating During Chemotherapy for Breast Cancer
Recruiting
Breast cancer is the most common cancer in the United States however, little is known about how diet can affect cancer treatment. Pre-clinical murine studies report intermittent fasting increases effectiveness of chemotherapy and decreases treatment related adverse events. The proposed research will demonstrate that time restricted eating, a form of intermittent fasting, will improve treatment related outcomes, patient related outcomes, and limit treatment related weight gain and fat mass accret... Read More
Gender:
FEMALE
Ages:
Between 25 years and 99 years
Trial Updated:
02/21/2025
Locations: University of Illinois Chicago, Chicago, Illinois
Conditions: Breast Cancer Female
Patient Navigators for Children's Community Mental Health Services in High Poverty Urban Communities
Recruiting
The purpose is to study a model of mental health navigation for African American and Latinx children (0-14 years) in high poverty urban communities focused on reducing key parental attitudinal barriers to care. Reducing persistent racial and ethnic disparities in children's mental health is a national priority and patient navigation is a highly promising approach that is rarely used in children's mental health services. The study will examine the effectiveness of paraprofessional (PP) navigators... Read More
Gender:
ALL
Ages:
14 years and below
Trial Updated:
02/20/2025
Locations: University of Illinois at Chicago, Chicago, Illinois
Conditions: Community Mental Health Services
Trial of Pre-operative Neratinib and Endocrine Therapy with Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
Recruiting
Patient will be treated with neratinib, an aromatase inhibitor and trastuzumab for 24 weeks prior to surgery, following an initial 3 weeks of neratinib alone, aromatase inhibitor alone or the combination of neratinib and an aromatase inhibitor. A breast biopsy will be performed prior to Day 1 of week 4 of treatment. Following surgery, patients will receive standard of care HER2-directed and endocrine therapy at the treating physician's discretion.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: University of Illinois Cancer Center, Chicago, Illinois
Conditions: Breast Cancer, HER2-positive Breast Cancer, ER Positive Breast Cancer, PR-Positive Breast Cancer
A Prospective, Clinical Investigation of the Vanguard 360 Revision Knee
Recruiting
The purpose of this study is to evaluate performance of the Vanguard 360 revision knee system utilizing offset on either the tibial component, femoral component, or both in terms of the restoration of mechanical alignment, clinical outcomes and survivorship.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: Illinois Bone and Joint, Morton Grove, Illinois
Conditions: Osteoarthritis, Rheumatoid Arthritis, Traumatic Arthritis, Post Traumatic Deformity, Complications; Arthroplasty, Deformity of Limb
Deep Functional Phenotyping of the ALA Lung Health Cohort
Recruiting
The goal of this observational study is to learn about lung structure and function in a group of 1000 healthy people aged 25 to 35. The main questions it aims to answer are whether people's bodies, environment, and general lung health are associated with:
* the structure of the participants lungs' airways,
* the structure of blood vessels in the participants lungs and heart, and
* the participants lungs' ability to exchange gases.
Participants will take four different lung function tests to me... Read More
Gender:
ALL
Ages:
Between 25 years and 35 years
Trial Updated:
02/19/2025
Locations: Northwestern University, Chicago, Illinois
Conditions: Lung Diseases
Study of Olutasidenib and Temozolomide in HGG
Recruiting
The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring an IDH1 mutation.
The main question the study aims to answer is whether the combination of olutasidenib and temozolomide (TMZ) can prolong the life of patients diagnosed with an IDH-mutant HGG.
Gender:
ALL
Ages:
Between 12 years and 39 years
Trial Updated:
02/19/2025
Locations: Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois
Conditions: High Grade Glioma, Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV, Diffuse Intrinsic Pontine Glioma, WHO Grade III Glioma, WHO Grade IV Glioma, Metastatic Brain Tumor, Diffuse Midline Glioma, H3 K27M-Mutant, Thalamus Tumor, Spinal Tumor, IDH1 Mutation, IDH1 R132, IDH1 R132C, IDH1 R132H, IDH1 R132S, IDH1 R132G, IDH1 R132L, Oligodendroglioma
International Rapid-onset Obesity with Hypothalamic Dysfunction, Hypoventilation & Autonomic Dysregulation (ROHHAD) Registry
Recruiting
The Center for Autonomic Medicine in Pediatrics (CAMP) has collaborated with doctors from around the world to build the first International ROHHAD (Rapid-onset Obesity with Hypothalamic Dysfunction, Hypoventilation and Autonomic Dysregulation) REDCap (Research Electronic Data Capture) Registry. This registry is an international collaboration with ROHHAD patients and their physicians recruited from around the world.
The purpose of this IRB-approved research study is to gain a better understandin... Read More
Gender:
ALL
Ages:
All
Trial Updated:
02/19/2025
Locations: Ann & Robert H. Lurie Children's Hospital of Chicago and the Stanley Manne Children's Research Institute, Chicago, Illinois
Conditions: ROHHAD, Rapid-Onset Obesity With Hypothalamic Dysfunction, Hypoventilation & Autonomic Dysregulation
Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease
Recruiting
This study is a randomized, double-blind, placebo-controlled trial specifically designed to evaluate the preliminary feasibility, initial efficacy and safety of SGLT2 inhibitors for treating NAFLD in adolescents with obesity.
Gender:
ALL
Ages:
Between 16 years and 20 years
Trial Updated:
02/18/2025
Locations: Ann & Robert H Lurie Children's Hospital of Chicago, Chicago, Illinois
Conditions: Non-Alcoholic Fatty Liver Disease
